[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,74,113,153,175,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100184467","tissue-collection-for-studies-of-lymph-cancer-100184467",false,"NCT01676805","Tissue Collection for Studies of Lymph Cancer","Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol","* LYMPHOID MALIGNANCIES\u002FDISEASES: The following criteria apply only to patients with a known lymphoid malignancy or precursor\n\ndisease, as described:\n\nINCLUSION CRITERIA:\n\n* Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia\u002Flymphoma (ATL).\n* Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.\n* Age \\>= 18 years of age\n* Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study.\n\nEXCLUSION CRITERIA:\n\n* Pregnant individuals will not be eligible.\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, and\u002For pulmonary dysfunction.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.\n\nNON-LYMPHOID MALIGNANCIES\u002FDISEASES: The following criteria apply only to patients without a known lymphoid malignancy or precursor disease, as described:\n\nINCLUSION CRITERIA:\n\n-Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)\u002Ftissue (i.e., those not with pre-determined likelihood of abnormality\u002F malignancy) may be obtained for research studies as part of this protocol.\n\nPatient is appropriate to undergo the surgical procedure planned, and consented for the same, as needed. NOTE: This study will not evaluate eligibility of the patient for surgery.\n\n* Age \\>= 18 years of age\n* Must be able and willing to sign informed consent\n\nEXCLUSION CRITERIA:\n\n* Pregnant individuals will not be eligible.\n* Other active malignancy. NOTE: Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for \\>=2 years will also be eligible at the discretion of the investigator.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.","ALL","18 Years",{"count":19,"type":20},1295,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia\u002Flymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue.\n\nObjectives:\n\n\\- To collect tissue samples to study different types of lymph cancer.\n\nEligibility:\n\n\\- Individuals at least 18 years of age who have a lymphoid cancer or precancer condition.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history.\n* Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study.\n* Treatment will not be provided as part of this study.",[24,25,26,27,28],"Hodgkin Disease","Lymphoma, Non-Hodgkin","Multiple Myeloma","Lymphomatoid Granulomatosis","Leukemia-Lymphoma, Adult T-Cell",[30,31,32,33,34,35],"Developing Novel Treatment Approaches","Developing Therapeutic Agents","Analysis of Genetic and Genomic Biology","New Prognostic and Diagnostic Models","Analysis of Cellular and Molecular Biology","Natural History","RECRUITING","2026-08-15",{"date":39,"type":40},"2026-08-18","ACTUAL",{"date":42,"type":40},"2012-09-21",{"name":44,"class":45},"National Cancer Institute (NCI)","NIH",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100261446","biospecimen-procurement-for-center-for-immuno-oncology-immunotherapy-protocols-100261446","NCT02682667","Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","* INCLUSION CRITERIA:\n\n  1. Diagnosis of cancer, a premalignant\u002Fneoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant\u002Fneoplastic condition\n  2. Age \\>=18 years of age\n  3. ECOG performance status of 0-3.\n\n  5\\. Ability and willingness of subject to provide informed consent\n\nAdditional inclusion criteria pertinent only for participants undergoing apheresis\n\n1. Hemoglobin \\>= 8 mg\u002FdL and platelet count \\> 75 K\u002FmicroL\n2. Weight \\>= 48 kg\n3. Central line in place or adequate venous access\n\nEXCLUSION CRITERIA:\n\n1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.\n2. Inability to provide informed consent\n3. Pregnant or breastfeeding women","120 Years",{"count":55,"type":20},500,"Background:\n\nCancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.\n\nObjective:\n\nTo better understand the biology of malignancies and why certain cancers respond differently to treatment.\n\nEligibility:\n\nAdults at least 18 years old with cancer or a pre-cancerous condition.\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.\n\nParticipants will send tissue blocks or slides from their original tumor biopsy.\n\nAt least once, participants will have a medical history, physical exam, and blood and urine tests.\n\nParticipants may have the following tests. They may have them more than once:\n\nApheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.\n\nBone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.\n\nPiece of cancer tissue taken by a needle and syringe.\n\nComputed tomography (CT) scan, magnetic resonance imaging (MRI) and\u002For positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.\n\nA small piece of skin removed.\n\nParticipants will be contacted by phone once a year to find out how they are doing.\n\n...",[26,25,28,24,58],"Non-Small Cell Lung Cancer",[60,61,62,63,64,35],"Apheresis Products","Immunological","Diverse Malignan","Premalignant","Protein","2026-08-14",{"date":67,"type":40},"2026-08-17",{"date":69,"type":40},"2016-04-11",{"date":71,"type":20},"2032-12-01",{"name":44,"class":45},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":73},"100481128","phase-1-anti-cd30-biab-aatc-in-patients-with-relapsedrefractory-cd30-positive-hematopoietic-malignancies-100481128","NCT05544968","Anti-CD30 biAb-AATC in Patients With Relapsed\u002FRefractory CD30 Positive Hematopoietic Malignancies","A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed\u002FRefractory CD30 Positive Hematopoietic Malignancies","Inclusion Criteria:\n\nDiagnosis: Patients must have had histologic or cytologic verification of the below qualified malignancy. The pathology report for the diagnosis under which the patient is being enrolled and associated molecular diagnostic reports must be submitted.\n\na. Hodgkin's Lymphoma (HD): Patients with HD are eligible with one of the following:\n\ni. Second or greater recurrence or refractory to at least 2 prior therapeutic regimens.\n\nii. Any relapse after HSCT.\n\nb. Non-Hodgkin Lymphoma (NHL): Patients with NHL are eligible with one of the following:\n\ni. Second or greater recurrence or refractory to at least 2 prior therapeutic regimens.\n\nii. Any relapse after HSCT or CAR T cell therapy.\n\nc. Acute Myeloid Leukemia (AML): Patients with AML are eligible with one of the following:\n\ni. First or greater relapse.\n\nii. Primary refractory disease with at least 1 prior induction attempts.\n\nd. Acute Lymphoblastic Leukemia (ALL): Patients with ALL are eligible with one of the following:\n\ni. Second or greater relapse or refractory to at least 2 prior therapeutic regimens.\n\nii. Any relapse after HSCT or CAR T cell therapy.\n\ne. Other Hematopoietic malignancy not listed above for which standard curative measures do not exist, are not proven to prolong survival with an acceptable quality of life, or are no longer effective.\n\nCD30 Expression Status: Disease specific histologic, cytologic, or Fluorescence-Activated Cell Sorting (FACS)-confirmed CD30 cell surface expression on malignant cells is required. CD30 surface expression must be confirmed at most recent histologic, cytologic, or FACS assessment of disease. This confirmation must occur at recurrence. No repeat CD30 expression verification is required for patients with primary refractory diseases. Pathology and diagnostic reports verifying the CD30 expression status must be submitted.\n\nLeukemia CD30 Expression Criteria: Flow cytometry immunophenotypic analysis of bone marrow or peripheral blood. Surface expression of CD30 expression on blasts \"positive\" with ≥20% expression consistent with established precedents.\n\nLymphoma CD30 Expression Criteria: Flow cytometry immunophenotypic analysis of lymphoma sample or immunohistochemical assessment of formalin-fixed paraffin embedded sample. Flow cytometry assessment surface expression or immunohistochemical membranous expression of CD30 on neoplastic cells \"positive\" with ≥ 1% expression consistent with established precedents.\n\nDisease Status:\n\ni. Lymphomas: Patients must have measurable disease for assessment of radiographic response defined as either nodal disease \\>\u002F=1.5 cm or extranodal lesion \\>\u002F=1.0 cm.\n\nii. Leukemias: Patients must have relapsed\u002Frefractory (including MRD \\>0.01% by flow cytometry) disease.\n\nPrior Therapy: Patients must have recovered from the acute toxic effects of prior anticancer chemotherapy, defined as resolution of all such toxicities to ≤ Grade 2 or lower prior to entering this study and initiating lymphocyte collection.\n\ni. Myelosuppressive chemotherapy: Patients must not have received myelosuppressive therapy within 3 weeks of apheresis for this study.\n\nii. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\n\niii. Biologic (anti-neoplastic agent): At least 7 days after the last of a biologic agent that is not a monoclonal antibody and infusion of study product on this study. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\n\niv. Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g., tumor vaccines or CAR T-cell therapy.\n\nv. Monoclonal antibodies: At least 3 half-lives must have elapsed after treatment with a monoclonal antibody and infusion of study product on this study.\n\nvi. XRT: \\>2 weeks must have elapsed for XRT and infusion of study product.\n\nvii. Prior treatment with etoposide, vincristine, CD30 targeted agent, or a bispecific antibody-armed activated autologous T-cell product as single agents or in combination are eligible for this study provided there were no known hypersensitivity or allergic reactions attributed to any of the components of compounds of similar composition to etoposide, vincristine, CD30 targeted agent, or a bispecific Antibody-armed activated autologous T cell product.\n\nAge: Patients must be ≥ 18 years at time of study enrollment.\n\nLife Expectancy: Life expectance of \\>12 weeks.\n\nPerformance Status: Karnofsky ≥50% for patients. Note: Neurologic deficits in patients with CNS involvement must have been stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n\nOrgan Function Requirements: Have acceptable organ function as defined below:\n\ni. Renal: Serum creatinine concentration ≤1.5 × institutional upper limit of normal (ULN) based on the age and sex, or creatinine clearance (CrCl) ≥50 mL\u002Fmin (as measured by Cockcroft-Gault formula or acceptable equivalent).\n\nii. Hepatic:\n\n1. Direct Bilirubin \\\u003C1.5 x upper limit of normal (ULN) for age. For patients with documented Gilbert's syndrome (unconjugated hyperbilirubinemia) the bilirubin must be ≤3 x ULN for age.\n2. SGPT (ALT) \\\u003C3 x ULN.\n3. Serum albumin \\>2 g\u002FdL.\n\niii. Pulmonary: Pulse oximetry \\>90% on room air. Subjects must have no supplemental oxygen requirement.\n\niv. Cardiac: LVEF ≥ 40% by ECHO or MUGA.\n\nv. HL and NHL specific criteria: Bone Marrow:\n\nAdequate bone marrow reserves as evidenced by the following: For patients with lymphoma without known bone marrow involvement:\n\ni. Peripheral absolute neutrophil count (ANC) ≥1,000\u002Fmm\\^3.\n\nii. Platelet count ≥50,000\u002Fmm\\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n\nb. For patients with known bone marrow disease or lymphoma with known bone marrow involvement will be eligible for study provided they meet the following transfusion criteria.\n\ni. Eligible regardless of ANC, hemoglobin or platelet counts provided they respond to red cell or platelet transfusions.\n\nii. They will not be eligible for assessment of hematologic toxicity.\n\nPregnancy: It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below.\n\n1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 7 days prior to enrollment.\n2. Female patients must meet one of the following:\n\ni. Postmenopausal for at least one year before the screening visit, or ii. Surgically sterile, or iii. If they are of childbearing potential, agree to practice a reliable method of contraception from the time of signing of the informed consent form through three months after the last dose of study drug. OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\] and withdrawal are not acceptable contraception methods.)\n\nc. Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:\n\ni. Practice effective barrier contraception during the entire study treatment period and through three months after the last study drug dose, OR agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\] and withdrawal are not acceptable methods of contraception.)\n\nConsent: Ability to under understand a written informed consent document, and the willingness to sign it. Voluntary written consent will be documented before initiation of study-related procedures not part of normal medical care. Consent may be withdrawn by the subject\u002Fguardian without prejudice to future medical care.\n\nExclusion Criteria\n\nPrior Therapy: Any toxicities from prior treatment, \\>Grade 3 per CTCAE v5.0 Hematopoietic stem cell transplantation (HCT) or chimeric antigen receptor T-cell therapy (CAR-T cell) within 60 days of enrollment, or evidence of veno-occlusive disease (VOD) at any time post-transplant.\n\nInvestigational Agent: Treatment with any investigational agent within 14 days of enrollment.\n\nExclusion Requirements Due to Comorbid Disease or Concurrent Illness:\n\nImmune: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Steroid premedication for imaging scans is allowed. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n\nInfectious: Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs\u002Fsymptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). Patients with possible fungal infections must have had appropriate anti-fungal antibiotics and adequately controlled. HIV-positive patients on combination antiretroviral therapy are ineligible because of the unknown ability to expand T cell populations for CD30 biAb-AATC product in this setting. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.\n\nPulmonary: Prior history of anti-CD30 therapy related pulmonary toxicity.\n\nNeurologic: Prior history of progressive multifocal leukoencephalopathy (PML).\n\nCardiac: Patients diagnosed with NYHA Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled hypertension.\n\nAllergies: Known hypersensitivity or allergic reaction attributed to any of the components of CD30 biAb-AATC or to compounds of similar composition to CD30 targeted agent, or a bispecific Antibody-armed activated autologous T cell product.\n\nPregnant or Breastfeeding: Pregnant or breastfeeding females will not be allowed to enroll on this study. Female patients with infants must agree not to breastfeed their infants during the entire study treatment period and through three months after the last study drug dose. Agents used in this study are known to be teratogenic to a fetus. There is there is no information on the excretion of CD30 biAb-AATC agents into breast milk but potential risk for adverse events in nursing infants secondary to treatment of the mother with a CD30 biAb-AATC.\n\nSecondary Malignancy: Patients should not have a history of any second malignancy in the last 1 year with exception of the diagnosis for inclusion; subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 1 year.",{"count":82,"type":20},42,"INTERVENTIONAL",[85],"PHASE1","This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).",[24,88,89,90,91,92,93],"CD30-Positive Diffuse Large B-Cell Lymphoma","CD30+ Anaplastic Large Cell Lymphoma","CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma","CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma","Leukemia","Lymphoma",[95,96,97,98,99,100,101,102],"CD30","Cancer","Bispecific","Cellular Therapy","T Cell","autologous","relapse","refractory","2026-03-30",{"date":105,"type":40},"2026-04-03",{"date":107,"type":40},"2026-03-04",{"date":109,"type":20},"2029-07",{"name":111,"class":112},"Medical College of Wisconsin","OTHER",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":83,"phases":124,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":73},"100609015","phase-2-pet-adapted-first-line-therapy-with-nivolumab-for-advanced-hodgkin-lymphoma-100609015","NCT07209059","PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma","A Single-Center Pilot Study Evaluating the Efficacy and Safety of First-Line Immunochemotherapy With Nivolumab Guided by Interim PET for Stratification and Hazard Minimization in Patients With Advanced Classical Hodgkin Lymphoma (FINISH-HL)","FINISH-HL","Inclusion Criteria:\n\n* Signed written informed consent prior to any study-specific procedures\n* Histologically confirmed classical Hodgkin lymphoma (cHL)\n* Newly diagnosed disease, Ann Arbor stage IIB (bulky), III, or IV\n* At least one measurable lesion ≥15 mm in the longest diameter (by CT)\n* Age between 18 and 60 years (inclusive)\n* ECOG performance status 0-2\n* PET-CT performed at baseline\n* No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma\n* Adequate organ function, including:\n* Serum creatinine ≤ 0.2 mmol\u002FL\n* Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction\n* Ability to comply with the study protocol and scheduled visits\n\nExclusion Criteria:\n\n* Active hepatitis B or C infection\n* Positive test for HIV\n* Pregnancy or breastfeeding\n* Prior or active autoimmune disease requiring systemic therapy\n* Vaccination with a live vaccine within 30 days prior to first nivolumab dose\n* History of non-infectious pneumonitis requiring corticosteroids\n* Prior malignancy (except for adequately treated basal cell carcinoma or cervical carcinoma in situ)\n* Congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias\n* Severe renal impairment (serum creatinine \\> 0.2 mmol\u002FL), unless lymphoma-related\n* Severe hepatic dysfunction, unless directly related to lymphoma\n* Severe pneumonia with respiratory failure or hypoxemia not corrected within 2-3 days\n* Sepsis or hemodynamic instability\n* Life-threatening bleeding events (e.g., gastrointestinal or cerebral hemorrhage)\n* Cachexia (total serum protein \\\u003C 35 g\u002FL), unless due to lymphoma-related liver damage\n* Decompensated diabetes mellitus\n* Any somatic or psychiatric condition that, in the investigator's judgment, precludes informed consent or study participation","60 Years",{"count":123,"type":20},30,[125],"PHASE2","This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.",[128,24,129],"Hodgkin Lymphoma","Advanced Hodgkin Lymphoma",[131,24,132,133,134,135,136,137,138,139,140,141,142],"Classical Hodgkin Lymphoma","Nivolumab","Immunotherapy","First-line treatment","PET-adapted therapy","Checkpoint inhibitors","ctDNA","Response-adapted treatment","EACOPD","AVD","PD-1 blockade","Circulating tumor DNA","2025-09-29",{"date":145,"type":40},"2025-10-06",{"date":147,"type":40},"2025-07-29",{"date":149,"type":20},"2028-12",{"name":151,"class":152},"National Research Center for Hematology, Russia","NETWORK",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":73},"100575595","role-of-spectral-ct-in-the-evaluation-of-cardiotoxicity-in-patients-with-hodgkins-lymphoma-and-diffuse-large-b-cell-lymphoma-treated-with-anthracyclines-100575595","NCT06774326","Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines","AntraCardioTox","Inclusion Criteria:\n\n* Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines\n* Age ≥18 years\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Absolute or relative contraindications to CT examination and\u002For administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \\\u003C15-30 ml\u002Fmin\u002F1.73m²).\n* Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies).\n* History of mediastinal radiotherapy.",{"count":161,"type":20},160,"To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens that include a drug from this family.",[164,165,93,24],"Cardiac Imaging","Cardiac Imaging Techniques","2025-01-09",{"date":168,"type":40},"2025-01-14",{"date":170,"type":40},"2024-02-14",{"date":172,"type":20},"2029-08",{"name":174,"class":112},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":83,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":73},"100568690","phase-1-atorvaststin-and-cardiotoxicity-in-acute-myloid-leukemia-100568690","NCT06684509","Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia","Using of Atorvastatin for Anthracyclin _ Associated Cardiotoxicity in Hemetological Malignancies Patients.","Inclusion Criteria:\n\nAge \\>18 years Patient with hematologic malignany ( Acute myeloid leukemia on 3,7 regimen or non-Hodkin Lymphoma on CHOP regimen) Cardiac function with EF ≥60%\n\nExclusion criteria:\n\nCardiac dysfunction with EF \\\u003C 60% Other hematologic malignancies Pregnant women and breastfeeding Patients refuse participate in research",{"count":183,"type":20},46,[85,125],"The research proposal focuses on evaluating the efficacy of atorvastatin in reducing cardiotoxicity caused by anthracycline chemotherapy in patients with hematologic malignancies, specifically acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL). The study will be conducted at Assiut University Hospitals and will include patients aged 18 or older receiving anthracycline-based treatments (3+7 regimen for AML and CHOP regimen for NHL).\n\nThe background highlights that anthracyclines, a class of chemotherapeutic agents, can cause serious side effects, particularly cardiotoxicity. The research aims to investigate whether atorvastatin, a statin used to lower cholesterol, can mitigate this risk by improving cardiac function in patients undergoing chemotherapy.\n\nThe study will be a randomized controlled trial with a sample size of 46 participants. It will assess left ventricular ejection fraction (LVEF) as the primary outcome to determine the effect of atorvastatin on reducing cardiotoxicity. Secondary outcomes include identifying high-risk patients and further understanding the impact of atorvastatin.\n\nThe study also adheres to ethical guidelines, ensuring patient consent and confidentiality. Data analysis will be performed using IBM SPSS, and results will be disseminated in scientific journals, with support from Assiut Medical School's Grants Office if funding is approved.",[92,24],[188,189],"Cardiotoxicity","Atrovastatin","NOT_YET_RECRUITING","2024-11-09",{"date":193,"type":40},"2024-11-12",{"date":195,"type":20},"2024-11",{"date":197,"type":20},"2029-09",{"name":199,"class":112},"Assiut University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":16,"minAge":17,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":83,"phases":212,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100525068","hodgkins-disease-and-chemotherapy-before-40-years-100525068","NCT06116929","Hodgkin's Disease and Chemotherapy Before 40 Years","Functional and Cognitive Assessment of Patients With Hodgkin's Disease Undergoing Chemotherapy Before 40 Years","FunC-AHOD","Inclusion criteria - case :\n\n* Patient with newly diagnosed Hodgkin's disease\n* With intention to treat with chemotherapy +\u002F- radiotherapy\n* Aged between 18 and 40 years\n* Fluency in French\n* Able to undergo neuropsychological evaluation (absence of major sensory disorders)\n* Agreeing to take part in the study and having signed the informed consent form\n* Affiliated with a social security scheme\n\nInclusion criteria - controls:\n\n* Individual without Hodgkin's disease\n* Aged between 18 and 40\n* Proficient in French\n* Agreeing to participate in the study and having signed the informed consent form\n* Affiliated with a social security scheme\n\nCases and controls will be matched on age (± 5 years difference), and number of years of education (difference ≤ 2 years).\n\nNon-inclusion criteria - cases + controls :\n\n* Claustrophobia preventing MRI from being performed\n* Contraindication to MRI\n* Previous chemotherapy\n* History of neurological or psychiatric illness, including severe depression, or cognitive impairment\n* Use of medications that may cause neurological or psychiatric signs\n* Alcohol or drug abuse\n* Pregnant women\n* Persons under guardianship or trusteeship",true,"40 Years",{"count":211,"type":20},63,[213],"NA","A few studies have focused on other solid cancers (colorectal, prostate). On the other hand, the study of cognitive impairment in Hodgkin's disease remains less developed, and structural and functional post-therapy MRI studies have never been carried out. The impact of cognitive impairment on Hodgkin's disease is rarely, if ever, assessed in routine clinical practice, despite the fact that it is truly disabling in 16 to 30% of patients. Cognitive impairment can persist long after diagnosis and treatment. A recent study examining cognitive functioning in patients an average of 13 years after treatment found that disorders persisted in 52% of cases, with attentional, working memory and dysexecutive (planning) difficulties. These disorders have a significant impact on the daily and professional lives of these young, often working patients. Their rapid development and persistence after treatment can therefore represent a real limiting factor, impacting both professional integration and quality of life. Finally, the current state of knowledge does not allow us to dissociate cognitive disorders from emotional disorders and fatigue, which represent a major patient complaint. A better definition of the nature, pathophysiology and specificity of these disorders would therefore enable us to take better account of their repercussions (social, professional and on quality of life) and provide better care (in terms of cognitive remediation or psychological support).\n\nA prospective, longitudinal, multicenter, case-control interventional study in which cases are patients with Hodgkin's disease (HD) treated with CT +\u002F- radiotherapy and controls are healthy participants will be conducted. The aim is to study the prevalence and nature of treatment-induced cognitive impairment and its correlation with emotional comorbidities, as well as structural and functional brain disorders on MRI. The patient will thus be his or her own witness, the reference state being that at the time of diagnosis, before any treatment. The fact that this state has not already been altered by the disease itself, will be verify thanks to comparison with controls.",[24],[24,217,218],"Chemotherapy","Functional and Cognitive Assessment","2024-02-26",{"date":221,"type":40},"2024-02-28",{"date":223,"type":20},"2024-05-15",{"date":225,"type":20},"2028-01-01",{"name":227,"class":112},"Lille Catholic University",4]